Metformin anti-tumor effect via disruption of the MID1 translational regulator complex and AR downregulation in prostate cancer cells


Creative Commons License

Demir U. , KOEHLER A., SCHNEIDER R., SCHWEIGER S., KLOCKER H.

BMC CANCER, cilt.14, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

Özet

Background: Metformin is an approved drug prescribed for diabetes. Its role as an anti-cancer agent has drawn significant attention because of its minimal side effects and low cost. However, its mechanism of anti-tumour action has not yet been fully clarified.